Johnson & Johnson vs Vanguard Ultra Short Bond ETF — how do they compare? Johnson & Johnson trades at $260.7 (market cap $626.09B), while Vanguard Ultra Short Bond ETF trades at $49.69. The key difference: Johnson & Johnson pays a 2.06% dividend while Vanguard Ultra Short Bond ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| JNJ | VUSB | |
|---|---|---|
Market Cap | $626.09B | — |
Volume | 6,156,228 | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $267.24 | $50.03 |
52-Week Low | $172.78 | $49.60 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | — |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
VUSB trades at $49.685, showing minimal daily movement with a 0.05% gain. Technical indicators signal a bearish trend, with moving averages and key momentum oscillators like the ADX indicating selling pressure. Recent news highlights the ETF's focus on short-term bonds amid expectations of Federal Reserve rate hikes, positioning it as a potential hedge against interest rate risk.
The outlook for VUSB is cautious due to bearish technical signals and sensitivity to interest rate changes. Opportunities lie in its short-term bond strategy if rates rise, but risks include market volatility and economic shifts. Investors should weigh the ETF's defensive role against prevailing macroeconomic uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →